

Company Statement



Hyloris Holding Statement -Ongoing Investigation

Liège, Belgium – 15 October 2026 – 10:00 AM - Hyloris Pharmaceuticals SA (“Hyloris”) (Euronext Brussels: HYL), the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, confirms that representatives of the authorities visited its Liège office on 14 October 2026.



During the visit, the authorities requested access to certain documents in connection with historical matters which have already been the subject of prior engagement with the FSMA. The underlying facts and circumstances are not new.

Hyloris continues to cooperate fully with the authorities and will inform the market when more news is available.

The company remains committed to transparency, responsible governance and compliance with applicable regulations. Hyloris's day-to-day business continues as normal, with focus on execution of its strategy, ongoing development programmes and commercial activities.



Press contacts



Ann De Jaeger

Chief Legal Officer & Communication

ann.dejaeger@hyloris.com

[+32 475 20 13 44](tel:+32475201344)